drugset / Trial / NCT01313884
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.
Timeline
- Start
- 2011-05
- Primary completion
- 2014-07
- Completion
- 2014-07
Outcome
Outcome not reported
Stopped (Enrollment): “Study did not reach primary objective; study did not accrue enough patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 1200 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 75 mg/m2 | — |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Background | Vincristine | Small molecule | 2 mg/m2 | — |